Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alector Inc.
With
GlaxoSmithKline
This is a Phase 2, multicenter, open label study evaluating the safety, tolerability, PK and PD of AL001 administered intravenously in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At screening, female participants must be nonpregnant and nonlactating
In good physical health on the basis of no clinically significant findings from medical history, physical examinations (PEs), laboratory tests, ECGs, and vital signs.
Participant is a carrier of a loss of function progranulin gene (GRN) mutation or carrier of a hexanucleotide repeat expansion C9orf72 mutation
You may not be if
Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
History of alcohol abuse or substance abuse
Participant resides in a skilled nursing facility, convalescent home, or long term care facility
Clareo Health | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
